Dynamin inhibitory peptide TFA

Dynamin Inhibitory Peptide TFA competitively inhibits the binding of dynamin to amphiphysin, effectively preventing endocytosis. Additionally, this compound impedes the dopamine D3's influence on GABA A receptors [1].

Dynamin inhibitory peptide, myristoylated acetate is a DynaMin inhibitor to interfere with the binding of amphiphysin with dynamin. DynaMin inhibitory peptide, myristoylated TFA is a membrane-permeant form of the peptide that prevents endocytosis.

IKKγ NBD Inhibitory Peptide acetate is a NEMO-binding domain peptide (NBD peptide) acetate corresponding to the NEMO amino-terminal alpha-helical region. IKKγ NBD Inhibitory Peptide acetate is shown to block TNF-alpha-induced NF-kB activation.

Autocamtide-2-related inhibitory peptide, myristoylated acetate is a CaM kinase II inhibitor; enhanced cell permeable derivative of Autocamtide-2-related inhibitory peptide.

3X FLAG peptide TFA (402750-12-3 free base) (3X FLAG peptide TFA) is a synthetic peptide of 23 amino acid residue. The Asp-Tyr-Lys-Xaa-Xaa-Asp motif is repeated three times in the peptide.

PKG inhibitor peptide TFA (82801-73-8 free base) is an inhibitor of ATP-competitive cGMP-dependent protein kinase (PKG).

RNAIII-inhibiting peptide TFA (RNAIII-inhibiting peptide(TFA))(228544-21-6 free base) inhibits S. aureus, effective in the diseases such as cellulitis, keratitis, septic arthritis, osteomylitis and mastitis.

C-MYC PEPTIDE EPITOPE TFA, the product of the c-myc proto-oncogene, is a helix-loop-helix leucine zipper phosphoprotein that regulates gene transcription in cell proliferation, cell differentiation and apoptosis. This peptide is a human c-myc epitope.

Gastrin-Releasing Peptide, human(TFA) is a regulatory human peptide that elicits gastrin release and regulates gastric acid secretion and enteric motor function. The post-ganglionic fibers of the vagus nerve that innervate the G cells of the stomach release GRP, which stimulates the G cells to release gastrin.

Dynamin inhibitory peptide Acetate is a peptide with the sequence Gln-Val-Pro-Ser-Arg-Pro-Asn-Arg-Ala-Pro that inhibit the GTPase dynamin.

Ras Inhibitory Peptide acetate is a peptide involved in the Ras-dependent signaling pathway that plays an important role in human cancers initiated by oncogenic receptors.

Antennapedia Peptide TFA (188842-14-0 free base), a peptide of 16 amino acids, is a member of the family of Cell-penetrating peptides, originally derived from the 60 amino acid long homeodomain of the Drosophila transcription factor Antennapedia.

Fibronectin Adhesion-promoting Peptide (Heparin Binding Peptide) is one of the heparin-binding amino acid sequences found in the carboxy-terminal heparin-binding domain of fibronectin. It promotes assembly of mesenchymal stem cell (MSC) spheroids into lar

Ptd-p65-p1 Peptide TFA is a nuclear transcription factor nf-kappab inhibitor, consisting of a membrane transport Peptide sequence derived from antennapedia linked to p65-p1, selectively inhibiting nf-kappab activity induced by various stimuli.

Klotho-derived peptide 1 (KP1) (56-87), a peptide originating from the human Klotho protein, disrupts TGF-β signaling by binding to TGF-β receptor types 1 and 2 (TGFBR1 and TGFBR2; Kds = 1.41 and 14.6 µM, respectively). Preincubation with KP1 at a concentration of 10 µg/ml hinders the TGF-β-induced escalation of fibronectin and α-smooth muscle actin (α-SMA) levels in NRK-49F rat fibroblasts. Furthermore, in vivo studies reveal that KP1, administered at 1 mg/kg per day, preferentially accumulates in damaged kidneys, leading to significant reductions in serum creatinine and blood urea nitrogen levels, indicators of improved kidney function. Additionally, it decreases kidney fibrosis in mouse models of unilateral ureteral obstruction (UUO) and unilateral ischemia-reperfusion injury-induced renal fibrosis.

Brain Natriuretic Peptide-45, rat TFA (BNP-45, rat TFA) is an isoform of rat brain natriuretic peptide extracted from rat heart, exhibiting significant hypotensive and natriuretic effects [1].

TREM-1 inhibitory peptide M3 acts as a ligand-dependent antagonist of TREM-1, capable of suppressing systemic and pulmonary pro-inflammatory cytokine and chemokine production, thereby mitigating acute lung injury [1].

OVA-E1 peptide TFA activates the p38 and JNK cascades similarly in mutant and wild-type thymocytes.

A cell-permeable synthetic peptide NEMO-binding domain peptide (NBD peptide) corresponding to the NEMO amino-terminal alpha-helical region is shown to block TNF-alpha-induced NF-kB activation. The interaction of IKγNEMO with the IKK complex is vital for t

Peptide T (TFA) is an octapeptide derived from the V2 region of HIV-1 gp120. It serves as a ligand for the CD4 receptor, effectively inhibiting the binding of HIV to the CD4 receptor.

OVA Peptide (257-264) TFA, an octameric peptide epitope from ovalbumin, is presented by the class I MHC molecule, H-2Kb, showcasing a class I (Kb)-restricted profile.

PTBP1α3-helix derived peptide P1 is a polypeptide that impedes RNA binding [1].

K1 peptide TFA exhibits high affinity as a ligand for the GABAA receptor-associated protein (GABARAP) [1].

Cell-permeable version of dynamin inhibitory peptide, an inhibitor of the GTPase dynamin that competitively blocks binding of dynamin to amphiphysin, preventing endocytosis. Reduces NMDA receptor internalization.

SLLK is a control peptide for LSKL.

PKG inhibitor peptide TFA is an ATP-competitive antagonist of cGMP-dependent protein kinase (PKG), exhibiting a K_i value of 86 μM [1].

Thioether-cyclized helix B peptide, CHBP (TFA), is the trifluoroacetic (TFA) salt of CHBP. This form enhances metabolic stability and exhibits renoprotective effects by promoting autophagy, achieved through the inhibition of mTOR C1 and activation of mTOR C2 [1].

Proteasome-activating peptide 1 TFA is a potent activator of the proteasome, enhancing chymotrypsin-like proteasomal catalytic activity and thereby increasing proteolytic rates both in vitro and in culture. Additionally, it inhibits protein aggregation in cellular models of amyotrophic lateral sclerosis (ALS) [1].

Tat-peptide 190-208 TFA is a Tat-labeled, cell-permeable fusion peptide derived from residues 190-208 of rat G3BP1. The HIV-derived Tat sequence, positioned at the peptide's least conserved region, confers cellular permeability. This compound promotes axon growth and enhances the formation of neurites per neuron, suggesting an axon intrinsic mechanism of action. Additionally, it has potential applications in providing ischemic protection during endovascular repair of intracranial aneurysms [1].

Tat-peptide 168-189, a cell-permeable, Tat-labeled fusion peptide derived from residues 168-189 of rat G3BP1, features the HIV Tat sequence at its least conserved terminus to enhance cellular uptake. It serves as the negative control for Tat-peptide 168-189 TFA, which promotes axon growth and neurite proliferation [1].

CCP Peptide TFA, a synthetic cyclic citrullinated peptide, serves as a serological substrate for the detection of anti-CCP antibodies and is a highly specific target for autoantibodies associated with rheumatoid arthritis (RA) [1] [2].

(Leu31,Pro34)-Peptide YY (human) (TFA) is the trifluoroacetic acid (TFA) form of (Leu31,Pro34)-Peptide YY (human), a derivative of Peptide YY that acts as a potent and selective Y1 agonist, exhibiting a dissociation constant (K D) of 1.0 nM [1].

Gastric inhibitory peptide 1 (GIP-1) (3-42), a fragment of the incretin hormone GIP and antagonist to the GIP receptor, is generated through the action of serum dipeptidyl peptidase 4 (DDP-4). When administered at 25 nmol/kg to an ob/ob mouse diabetes model, GIP-1 (3-42) elevates plasma glucose levels and lowers plasma insulin levels, demonstrating its effect on reducing insulin secretion from BRIN-BD11 pancreatic cells at a concentration of 100 nM.

Autocamtide-2-related inhibitory peptide is a highly specific and potent inhibitor of CaMKII with an IC50 of 40 nM.

IKKγ NBD Inhibitory Peptide TFA is a specific NF-κB inhibitor that functions by hindering the interaction between the IKKγ/NEMO-binding domain (NBD) and IKKα and IKKβ. This action effectively prevents TNF-α-induced NF-kB activation. It has been demonstrated to significantly suppress inflammation and improve neurological deficits induced by cerebral ischemia [1] [2] [3].

AMARA peptide (TFA) serves as a substrate for both salt-inducible kinase (SIK) and adenosine monophosphate-activated protein kinase (AMPK).

Autocamtide-2-related inhibitory peptide (TFA) acts as a highly specific and potent CaMKII inhibitor, exhibiting an IC50 value of 40 nM.

Myristoylated Autocamtide-2-related inhibitory peptide, trifluoroacetic acid (TFA) form, is a potent and highly specific inhibitor of CaMKII, exhibiting an IC50 of 40 nM [1]. This compound constitutes the myristoylated variant of Autocamtide-2-related inhibitory peptide.

Sakamototide substrate peptide TFA is a peptide substrate of AMPK kinase family and can be used for the determination of kinase activity.

Glucagon-like peptide 1 (1-37), human (TFA) is a highly potent agonist of the GLP-1 receptor, it is a kind of pancreatic hormone synthesized by post-translational processing of proglucagon.

Control peptide version of dynamin inhibitory peptide, myristoylated, an inhibitor of the GTPase dynamin that competitively blocks binding of dynamin to amphiphysin, preventing endocytosis. In contrast to dynamin inhibitory peptide, has no significant eff

Transdermal Peptide TFA (TD 1 Peptide TFA) is an 11-amino acid polypeptide that binds to Na+/K+ -atpase beta-subunit (ATP1B1) and interacts with the C terminal of ATP1B1.Transdermal Peptide TFA can enhance the transmission of some large molecules in the s

EGFR peptide (myristoylated), a synthetic peptide inhibitor of PKC (IC50 = 5 µM), corresponds to the intracellular region's amino acid sequence of EGFR. It effectively reverses doxorubicin resistance in UV-2237M (UV-2237M-ADRR) fibrosarcoma cells at a concentration of 1 µM.

Renin inhibitory peptide, statine is a effective, specific statine-containing renin inhibitor.

[Tyr0] Gastric Inhibitory Peptide (23-42), human, functions as a glucose-dependent insulinotropic polypeptide (GIP) and exhibits dual activity: it modestly inhibits gastric acid secretion while simultaneously enhancing insulin secretion. This characteristic makes it applicable in research related to diabetes and obesity [1] [2].

Bim BH3, Peptide IV TFA, is a 26-residue peptide derived from the BH3-only protein Bim, a member of the pro-apoptotic Bcl-2 protein family [1] [2].

Calcitonin Gene-Related Peptide (CGRP) II, rat TFA, functions as a potent and enduring vasodilator by activating CGRP receptors. This compound is utilized in cardiovascular disease research [1].

Peptide YY (PYY) (3-36), porcine TFA, functions as a gut hormone that serves as a Y2 receptor agonist, effectively reducing appetite [1].

Akt/SKG Substrate Peptide TFA is a synthetic peptide designed as a substrate specifically for Akt/PKB and is not phosphorylated by p70S6K or MAPK1 [1].

RGD peptide (GRGDNP) TFA functions as an inhibitor of integrin-ligand interactions, competitively blocking α5β1's interaction with the extracellular matrix (ECM). It induces apoptosis by triggering conformational changes that facilitate pro-caspase-3 activation and autoprocessing. Furthermore, RGD peptide (GRGDNP) TFA is critical in regulating cell adhesion, migration, growth, and differentiation [1] [2] [3].